Who are Isoniazid (Rifinah)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Isoniazid (INH), Rifampin/isoniazid FDC, Isoniazid Aminosalicylate Tablets, Isoniazid with Ethambutol, Isoniazid (H), Pyrazinamide Oral Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isoniazid-rifinah.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Isoniazid (Rifinah) — Competitive Intelligence Brief

Isoniazid (Rifinah) (Isoniazid (Rifinah)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antituberculous agent. Area: Infectious Disease.

marketed Antituberculous agent Enoyl-ACP reductase (InhA) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Isoniazid (Rifinah) (Isoniazid (Rifinah)) — National Taiwan University Hospital. Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Isoniazid (Rifinah) TARGET	Isoniazid (Rifinah)	National Taiwan University Hospital	marketed	Antituberculous agent	Enoyl-ACP reductase (InhA)
Isoniazid (INH)	Isoniazid (INH)	National Institutes of Health Clinical Center (CC)	marketed	Antituberculous agent	InhA (enoyl-ACP reductase)
Rifampin/isoniazid FDC	Rifampin/isoniazid FDC	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antituberculous agent (fixed-dose combination)	Bacterial RNA polymerase (rifampin); mycolic acid biosynthesis (isoniazid)
Isoniazid Aminosalicylate Tablets	Isoniazid Aminosalicylate Tablets	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Antituberculous agent combination	Mycobacterial catalase-peroxidase (KatG), mycolic acid synthesis, folate metabolism
Isoniazid with Ethambutol	Isoniazid with Ethambutol	Tuberculosis Research Centre, India	phase 3	Antituberculous agents	InhA (isoniazid); arabinosyl transferases (ethambutol)
Isoniazid (H)	Isoniazid (H)	University College, London	phase 3	Nicotinamide analog; first-line antituberculous agent	Enoyl-ACP reductase (InhA); catalase-peroxidase (KatG)
Pyrazinamide Oral Product	Pyrazinamide Oral Product	Wits Health Consortium (Pty) Ltd	phase 3	Antituberculous agent	Pantothenate synthetase (PanC); pyrazinamidase activation required

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antituberculous agent class)

National Taiwan University Hospital · 2 drugs in this class
Wits Health Consortium (Pty) Ltd · 2 drugs in this class
National Institutes of Health Clinical Center (CC) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Isoniazid (Rifinah) — Competitive Intelligence Brief. https://druglandscape.com/ci/isoniazid-rifinah. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab